glp-1 gerd Agonists: A Comprehensive Overview Does GLP-1 Give You Heartburn?

Obes Res Clin Pract 2025;19:77-9.ArticlePubMed 99

Conclusion This study provides preliminary evidence in support of GLP-1 based therapies in providing beneficial effects against atherosclerosis as this therapeutic regimen was found to be associated with statistically significant reductions in the plasma levels of atherosclerosis markers including plasminogen activator inhibitor-1, high sensitivity c-reactive protein and brain natriuretic peptide

Obes Rev 15(7):578586

In the coming years, several trends are likely to emerge: Rapid growth in the number of oral GLP-1 drugs Small-molecule GLP-1 therapies becoming a major R&D focus Manufacturing capacity becoming a key competitive factor Continued entry of emerging biotechnology companies into the sector At the same time, dual-target GLP-1 drugs , GLP-1/GIP co-agonists , and oral multi-target metabolic therapies are also advancing rapidly